{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:12Z","timestamp":1793412012519,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is unknown how many mantle cell lymphoma (MCL) patients undergo consolidation with autologous hematopoietic cell transplantation (AHCT), and the reasons governing the decision, are also unknown. The prognostic impact of omitting AHCT is also understudied. We identified all MCL patients diagnosed from 2000 to 2014, aged 18 to 65 years, in the Swedish Lymphoma Register. Odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models were used to compare the likelihood of AHCT within 18 months of diagnosis. All-cause mortality was compared between patients treated with\/without AHCT using hazard ratios (HRs) and 95% CIs estimated from Cox regression models. Probabilities of being in each of the following states: alive without AHCT, alive with AHCT, dead before AHCT, and dead after AHCT, were estimated over time from an illness-death model. Among 369 patients, 148 (40%) were not treated with AHCT within 18 months. Compared with married patients, never married and divorced patients had lower likelihood of undergoing AHCT, as had patients with lower educational level, and comorbid patients. Receiving AHCT was associated with reduced all-cause mortality (HR = 0.58, 95% CI: 0.40-0.85). Transplantation-related mortality was low (2%). MCL patients not receiving an AHCT had an increased mortality rate, and furthermore, an undue concern about performing an AHCT in certain societal groups was seen. Improvements in supportive functions potentially increasing the likelihood of tolerating an AHCT and introduction of more tolerable treatments for these groups are needed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003645","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T16:35:22Z","timestamp":1615566922000},"page":"1638-1647","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics, and Pathology, Clinical and Experimental Oncology, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden;"},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Division of Hematology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Albertsson-Lindblad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Crowther","sequence":"additional","affiliation":[{"name":"Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, United Kingdom; and"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-8183","authenticated-orcid":false,"given":"Caroline E.","family":"Weibull","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"1","key":"2021031216351692100_B1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients\u2014a nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"},{"issue":"16","key":"2021031216351692100_B2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2021031216351692100_B3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2021031216351692100_B4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021031216351692100_B5","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2021031216351692100_B6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2021031216351692100_B7","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"2021031216351692100_B8","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1080\/10428194.2019.1605511","article-title":"Mantle cell lymphoma: therapeutic options in transplant-ineligible patients","volume":"60","author":"Robak","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021031216351692100_B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11899-019-00520-0","article-title":"Mantle cell lymphoma: which patients should we transplant?","volume":"14","author":"Gerson","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2021031216351692100_B10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2021031216351692100_B11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17474086.2019.1588106","article-title":"When to use stem cell transplant in mantle cell lymphoma","volume":"12","author":"Greenwell","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2021031216351692100_B12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021031216351692100_B13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2021031216351692100_B14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11764-015-0436-0","article-title":"Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time\u2013a population-based comparative study [published correction appears in J Cancer Surviv. 2015;9(4):610-611]","volume":"9","author":"Glimelius","year":"2015","journal-title":"J Cancer Surviv"},{"issue":"9","key":"2021031216351692100_B15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2021031216351692100_B16","volume-title":"Causality: Models, Reasoning, and Inference","author":"Pearl","year":"2000"},{"issue":"29","key":"2021031216351692100_B17","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1002\/sim.7448","article-title":"Parametric multistate survival models: flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences","volume":"36","author":"Crowther","year":"2017","journal-title":"Stat Med"},{"issue":"22","key":"2021031216351692100_B18","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1002\/sim.6191","article-title":"Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis","volume":"33","author":"Crowther","year":"2014","journal-title":"Stat Med"},{"issue":"7","key":"2021031216351692100_B19","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2021031216351692100_B20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2021031216351692100_B21","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2017.11.002","article-title":"Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single-institution experience","volume":"18","author":"Sawalha","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2021031216351692100_B22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","article-title":"Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma","volume":"50","author":"Tam","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021031216351692100_B23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"2021031216351692100_B24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hon.2618","article-title":"A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma","volume":"37","author":"Ng","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2021031216351692100_B25","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/leu.2015.322","article-title":"Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials","volume":"30","author":"Hoster","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2021031216351692100_B26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","article-title":"Autologous hematopoietic stem cell transplantation in elderly patients (\u226570 years) with non-Hodgkin\u2019s lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study","volume":"6","author":"Hermet","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"2021031216351692100_B27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2021031216351692100_B28","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"2021031216351692100_B29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2021031216351692100_B30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bjh.16257","article-title":"Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP","volume":"188","author":"Jeon","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1638\/1802482\/advancesadv2020003645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1638\/1802482\/advancesadv2020003645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T16:35:36Z","timestamp":1615566936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1638\/475198\/Unmarried-or-less-educated-patients-with-mantle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003645","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}